当前位置: X-MOL 学术Nat. Rev. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
First-line PARP inhibition in ovarian cancer - standard of care for all?
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2020-03-01 , DOI: 10.1038/s41571-020-0335-9
Susana N Banerjee 1 , Christopher J Lord 2
Affiliation  

In 2018, the SOLO1 trial set a new standard of care with maintenance olaparib substantially extending progression-free survival (PFS) in women with newly-diagnosed BRCA1/2-mutated advanced-stage ovarian cancer. Herein, we summarize trials of first-line poly(ADP-ribose) polymerase (PARP) inhibition beyond BRCA1/2 mutations, including combination strategies, and discuss the optimum use of PARP inhibition in advanced-stage ovarian cancer.

中文翻译:


卵巢癌的一线 PARP 抑制——所有人的护理标准?



2018 年,SOLO1 试验制定了新的护理标准,奥拉帕尼维持治疗可显着延长新诊断的 BRCA1/2 突变晚期卵巢癌女性的无进展生存期 (PFS)。在此,我们总结了 BRCA1/2 突变以外的一线聚(ADP-核糖)聚合酶(PARP)抑制试验,包括联合策略,并讨论了 PARP 抑制在晚期卵巢癌中的最佳使用。
更新日期:2020-02-12
down
wechat
bug